Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.

Abstract

Pegylated liposomal doxorubicin (PLD) is usually used in disseminated HIV-related Kaposi's sarcoma (KS). It is the first-line treatment or second-line therapy in patients who do not tolerate or do not respond to polychemotherapy since 1995, when it was approved by the FDA. We report two cases of disseminated classic KS not associated with immunosuppression in which HHV-8 infection was demonstrated. They showed an excellent response to PLD, with good tolerance and an absence of side effects.

• Authors: Iria Castiñeiras, Manuel Almagro, Jesús Rodríguez-Lozano, Beatriz Fernández-Jorge, Sabela Paradela, Jesús Del Pozo, Eduardo Fonseca
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 17 Issue 6 Pg. 377-80 ( 2006) ISSN: 0954-6634 [Print] England
• PMID: 17853313 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• liposomal doxorubicin
• Polyethylene Glycols
• Doxorubicin

Topics

• Antibiotics, Antineoplastic (therapeutic use)
• Doxorubicin (analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged
• Polyethylene Glycols (therapeutic use)
• Sarcoma, Kaposi (drug therapy, pathology)
• Skin Neoplasms (drug therapy, pathology)